Boehringer stroke prevention drug gets FDA recommendation
Boehringer Ingelheim said that the current recommendations for patients with non-valuvlar atrial fibrillation treated with Warfarin recommend maintaining an international normalised ratio (INR) in the range of 2.0-3.0
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.